8-K: Encompass Health Reports Strong Q4 2024 Results and Issues Optimistic 2025 Guidance

Encompass Health reports a robust fourth quarter in 2024, driven by discharge growth and issues a promising outlook for 2025.

Summary

• Encompass Health Corporation (NYSE: EHC) reported its Q4 2024 results, showcasing significant growth.
• Net operating revenue increased by 12.7% to $1,405.0 million compared to $1,246.8 million in Q4 2023.
• Income from continuing operations attributable to Encompass Health per diluted share rose by 25.5% to $1.18.
• Adjusted earnings per share increased by 23.2% to $1.17.
• Cash flows provided by operating activities surged by 38.7% to $278.8 million.
• Adjusted EBITDA grew by 13.6% to $289.6 million.
• Discharges increased by 7.8%, with same-store discharge growth at 5.8%.
• Net patient revenue per discharge grew by 4.2% to $21,399.
• For the full year 2024, net operating revenue increased by 11.9% and Adjusted EBITDA grew by 13.7%.
• The company added 427 beds in 2024 through new hospitals and bed additions.
• Encompass Health provided 2025 guidance, projecting net operating revenue between $5,800 and $5,900 million.
• Adjusted EBITDA for 2025 is expected to be between $1,160 and $1,200 million.
• Adjusted earnings per share from continuing operations attributable to Encompass Health are projected to be between $4.67 and $4.96.

Sentiment

Score: 9

Explanation: The document presents a highly positive outlook with strong financial results, optimistic future guidance, and strategic growth initiatives. The tone is confident and forward-looking.

Positives

• Significant revenue growth of 12.7% in Q4 2024.
• Substantial increase in cash flows from operating activities, up 38.7%.
• Strong Adjusted EBITDA growth of 13.6% in Q4 2024.
• Increase in discharges by 7.8% indicating higher patient volume.
• Positive 2025 guidance for revenue, EBITDA, and EPS.
• Capacity expansion with the addition of 427 beds in 2024.
• Net leverage decreased to 2.2x at year-end 2024 compared to 2.7x at year-end 2023.
• Adjusted free cash flow increased 103.7% to $190.5 million in Q4 2024.
• Same-store discharge growth was 5.8% in Q4 2024.
• Net patient revenue per discharge grew 4.2% to $21,399 in Q4 2024.

Negatives

• Loss on early extinguishment of debt of $0.2 million in Q4 2024.
• Asset impairment impact on noncontrolling interests of $7.3 million.
• Increased cash taxes primarily due to higher income, the phase-out of bonus depreciation and 2023 cash taxes benefiting from an $11 million overpayment in 2022.
• Increased maintenance CAPEX related to major renovation projects and programmatic hospital asset replacements.

Risks

• Infectious disease outbreaks could decrease patient volumes and revenues.
• Economic downturns could affect demand for services.
• Adverse outcomes from lawsuits or regulatory proceedings.
• Disruptions to information systems could impact patient care.
• Inability to successfully integrate acquired operations.
• Changes in healthcare regulations could affect reimbursement.
• Competitive pressures in the healthcare industry.
• Inability to attract and retain healthcare professionals.
• General economic and capital market conditions.
• Increases in the cost of defending and insuring against alleged professional liability claims.

Future Outlook

Encompass Health anticipates net operating revenue between $5,800 and $5,900 million, Adjusted EBITDA between $1,160 and $1,200 million, and adjusted earnings per share between $4.67 and $4.96 for 2025.

Management Comments

• The fourth quarter was a very strong finish to 2024, said President and Chief Executive Officer of Encompass Health Mark Tarr.
• Discharge growth of 7.8% facilitated an increase of 12.7% in net operating revenue and an increase of 13.6% in Adjusted EBITDA.
• For the full year, net operating revenue increased 11.9% and Adjusted EBITDA grew 13.7%.
• In 2024, we increased our capacity by a total of 427 beds through new hospitals and bed additions to existing hospitals.
• Our value proposition and operating strategy continue to be validated and we remain bullish on the long-term prospects of our business.

Industry Context

Encompass Health, as the largest owner and operator of inpatient rehabilitation hospitals in the United States, benefits from favorable demographics driving increased demand for rehabilitation services and significant barriers to entry in the sector. The company's growth strategy, including de novo developments and bed additions, positions it well to capitalize on the under penetrated inpatient rehabilitation market.

Comparison to Industry Standards

• Encompass Health's performance can be compared to other major players in the healthcare services industry, such as Select Medical Holdings Corporation and Kindred Healthcare (although Kindred is now primarily a nursing home operator after selling its rehab facilities).
• Encompass Health's focus on inpatient rehabilitation hospitals differentiates it from companies with a broader range of healthcare services.
• The company's growth in revenue and EBITDA is indicative of its strong market position and operational efficiency.
• The company's expansion strategy through de novo hospitals and bed additions is similar to strategies employed by other healthcare providers to increase capacity and market share.
• Encompass Health's leverage ratio of 2.2x is within a reasonable range for companies in the healthcare services sector, indicating a healthy balance sheet.

Stakeholder Impact

• Shareholders can expect continued growth and potential returns through dividends and share repurchases.
• Employees may benefit from the company's growth and expansion.
• Patients will have access to high-quality rehabilitative care through Encompass Health's network of hospitals.
• Suppliers can expect continued business opportunities with Encompass Health.
• Creditors can be assured of the company's ability to service its debt.

Next Steps

• The company will host an investor conference call on February 7, 2025, to discuss the results.
• Encompass Health plans to continue its growth strategy through de novo developments and bed additions.
• The company will focus on managing costs and improving operational efficiency.
• Encompass Health will continue to evaluate opportunities for shareholder distributions, including dividends and share repurchases.

Key Dates